{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:22:59Z","timestamp":1791433379051,"version":"4.3.3"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02324-y","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:38:39Z","timestamp":1778668719000},"page":"989-1012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bruton\u2019s Tyrosine Kinase Inhibitors in Multiple Sclerosis"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-0988","authenticated-orcid":false,"given":"Jeffrey","family":"Lambe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-3717","authenticated-orcid":false,"given":"Robert J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"9648","key":"2324_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(08)61620-7.","journal-title":"Lancet"},{"issue":"1","key":"2324_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","volume":"85","author":"A Scalfari","year":"2014","unstructured":"Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(1):67\u201375. https:\/\/doi.org\/10.1136\/jnnp-2012-304333.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"24","key":"2324_CR3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","volume":"94","author":"FD Lublin","year":"2020","unstructured":"Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ, on behalf of the International Advisory Committee on Clinical Trials in MS. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology. 2020;94(24):1088\u201392. https:\/\/doi.org\/10.1212\/WNL.0000000000009636.","journal-title":"Neurology"},{"issue":"12","key":"2324_CR4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1177\/1352458517729455","volume":"23","author":"H Lassmann","year":"2017","unstructured":"Lassmann H. Targets of therapy in progressive MS. Mult Scler J. 2017;23(12):1593\u20139. https:\/\/doi.org\/10.1177\/1352458517729455.","journal-title":"Mult Scler J"},{"issue":"Suppl 2(Suppl 2","key":"2324_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jnc.13607","volume":"139","author":"DJ DiSabato","year":"2016","unstructured":"DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016;139(Suppl 2(Suppl 2)):136\u201353. https:\/\/doi.org\/10.1111\/jnc.13607.","journal-title":"J Neurochem"},{"issue":"4","key":"2324_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41582-022-00624-x","volume":"18","author":"LM Healy","year":"2022","unstructured":"Healy LM, Stratton JA, Kuhlmann T, Antel J. The role of glial cells in multiple sclerosis disease progression. Nat Rev Neurol. 2022;18(4):237\u201348. https:\/\/doi.org\/10.1038\/s41582-022-00624-x.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"2324_CR7","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1179\/1743132812Y.0000000072","volume":"34","author":"A Minagar","year":"2012","unstructured":"Minagar A, Maghzi AH, McGee JC, Alexander JS. Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy. Neurol Res. 2012;34(8):738\u201345. https:\/\/doi.org\/10.1179\/1743132812Y.0000000072.","journal-title":"Neurol Res"},{"issue":"1","key":"2324_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02408-y","volume":"19","author":"E Kamma","year":"2022","unstructured":"Kamma E, Lasisi W, Libner C, Ng HS, Plemel JR. Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. J Neuroinflammation. 2022;19(1):45. https:\/\/doi.org\/10.1186\/s12974-022-02408-y.","journal-title":"J Neuroinflammation"},{"key":"2324_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211066751","volume":"15","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobaeus E, Jensen MB, et al. Smouldering multiple sclerosis: the \u201creal MS.\u201d Ther Adv Neurol Disord. 2022;15:17562864211066751. https:\/\/doi.org\/10.1177\/17562864211066751.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"2324_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/WCO.0000000000001369","volume":"38","author":"J Lambe","year":"2025","unstructured":"Lambe J, Ontaneda D. Re-defining progression in multiple sclerosis. Curr Opin Neurol. 2025;38(3):188\u201396. https:\/\/doi.org\/10.1097\/WCO.0000000000001369.","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"2324_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568.","journal-title":"JAMA Neurol"},{"issue":"11","key":"2324_CR12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller J, Cagol A, Lorscheider J, Tsagkas C, Benkert P, Yaldizli \u00d6, et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol. 2023;80(11):1232. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3331.","journal-title":"JAMA Neurol"},{"issue":"2","key":"2324_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur C, Carbonell-Mirabent P, Cobo-Calvo \u00c1, Otero-Romero S, Arrambide G, Midaglia L, et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in Multiple Sclerosis. JAMA Neurol. 2023;80(2):151. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4655.","journal-title":"JAMA Neurol"},{"issue":"8","key":"2324_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of Multiple Sclerosis: a review. JAMA. 2021;325(8):765. https:\/\/doi.org\/10.1001\/jama.2020.26858.","journal-title":"JAMA"},{"issue":"3","key":"2324_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","volume":"84","author":"AK Carlson","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA. Drugs targeting CD20 in Multiple Sclerosis: pharmacology, efficacy, safety, and tolerability. Drugs. 2024;84(3):285\u2013304. https:\/\/doi.org\/10.1007\/s40265-024-02011-w.","journal-title":"Drugs"},{"issue":"11","key":"2324_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40263-022-00961-x","volume":"36","author":"X Wu","year":"2022","unstructured":"Wu X, Tan X, Zhang J, Wang Z, Wu W, Wang S, et al. The efficacy and safety of Anti-CD20 antibody treatments in relapsing Multiple Sclerosis: a systematic review and network meta-analysis. CNS Drugs. 2022;36(11):1155\u201370. https:\/\/doi.org\/10.1007\/s40263-022-00961-x.","journal-title":"CNS Drugs"},{"key":"2324_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/2025.11.12.25340116","author":"Z Gan","year":"2025","unstructured":"Gan Z, Zhu W, Tang W, Sweet SM, Morris M, Han Y, et al. Knowledge graph-guided identification of multiple sclerosis and therapeutic trend analysis: real-world evidence from two large healthcare systems. MedRxiv Prepr Serv Health Sci. 2025. https:\/\/doi.org\/10.1101\/2025.11.12.25340116.","journal-title":"MedRxiv Prepr Serv Health Sci."},{"issue":"3","key":"2324_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","volume":"23","author":"J Chataway","year":"2024","unstructured":"Chataway J, Williams T, Li V, Marrie RA, Ontaneda D, Fox RJ. Clinical trials for progressive Multiple Sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol. 2024;23(3):277\u2013301. https:\/\/doi.org\/10.1016\/S1474-4422(24)00027-9.","journal-title":"Lancet Neurol"},{"issue":"5","key":"2324_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.27034","volume":"96","author":"A Scalfari","year":"2024","unstructured":"Scalfari A, Traboulsee A, Oh J, Airas L, Bittner S, Calabrese M, et al. Smouldering\u2010associated worsening in Multiple Sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions. Ann Neurol. 2024;96(5):826\u201345. https:\/\/doi.org\/10.1002\/ana.27034.","journal-title":"Ann Neurol"},{"key":"2324_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60\u20135. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.009.","journal-title":"J Autoimmun"},{"key":"2324_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1380654","author":"A Elgenidy","year":"2024","unstructured":"Elgenidy A, Abdelhalim NN, Al-kurdi MAmahdi, Mohamed LA, Ghoneim MM, Fathy AW, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients. Front Neurol. 2024. https:\/\/doi.org\/10.3389\/fneur.2024.1380654.","journal-title":"Front Neurol"},{"key":"2324_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13133-w","author":"L Davies","year":"2025","unstructured":"Davies L, Shehadeh R, Watkins WJ, Jolles S, Robertson NP, Tallantyre EC. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. J Neurol. 2025. https:\/\/doi.org\/10.1007\/s00415-025-13133-w.","journal-title":"J Neurol"},{"issue":"1","key":"2324_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-146","volume":"8","author":"K Lehmann-Horn","year":"2011","unstructured":"Lehmann-Horn K, Schleich E, Hertzenberg D, Hapfelmeier A, K\u00fcmpfel T, von Bubnoff N, et al. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation. 2011;8(1):146. https:\/\/doi.org\/10.1186\/1742-2094-8-146.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"2324_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.14670\/HH-20.945","volume":"20","author":"C Brunner","year":"2005","unstructured":"Brunner C, M\u00fcller B, Wirth T. Bruton\u2019s Tyrosine Kinase is involved in innate and adaptive immunity. Histol Histopathol. 2005;20(3):945\u201355. https:\/\/doi.org\/10.14670\/HH-20.945.","journal-title":"Histol Histopathol"},{"issue":"2","key":"2324_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","volume":"24","author":"TJ Turner","year":"2024","unstructured":"Turner TJ, Brun P, Gruber RC, Ofengeim D. Comparative CNS pharmacology of the Bruton\u2019s Tyrosine Kinase (BTK) inhibitor Tolebrutinib versus other BTK inhibitor candidates for treating Multiple Sclerosis. Drugs R D. 2024;24(2):263\u201374. https:\/\/doi.org\/10.1007\/s40268-024-00468-4.","journal-title":"Drugs R D"},{"issue":"6","key":"2324_CR26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722\u20138.","journal-title":"Pediatrics"},{"issue":"2","key":"2324_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-f","volume":"72","author":"S Tsukada","year":"1993","unstructured":"Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279\u201390. https:\/\/doi.org\/10.1016\/0092-8674(93)90667-f.","journal-title":"Cell"},{"issue":"6409","key":"2324_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/361226a0","volume":"361","author":"D Vetrie","year":"1993","unstructured":"Vetrie D, Vo\u0159echovsk\u00fd I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226\u201333. https:\/\/doi.org\/10.1038\/361226a0.","journal-title":"Nature"},{"issue":"3\u20134","key":"2324_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1359-6101(99)00019-2","volume":"10","author":"H Mano","year":"1999","unstructured":"Mano H. Tec family of protein-tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev. 1999;10(3\u20134):267\u201380. https:\/\/doi.org\/10.1016\/S1359-6101(99)00019-2.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"16","key":"2324_CR30","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","volume":"119","author":"LP Kil","year":"2012","unstructured":"Kil LP, de Bruijn MJW, van Nimwegen M, Corneth OBJ, van Hamburg JP, Dingjan GM, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012;119(16):3744\u201356. https:\/\/doi.org\/10.1182\/blood-2011-12-397919.","journal-title":"Blood"},{"issue":"7","key":"2324_CR31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1084\/jem.20040920","volume":"200","author":"YS Ng","year":"2004","unstructured":"Ng YS, Wardemann H, Chelnis J, Cunningham-Rundles C, Meffre E. Bruton\u2019s tyrosine kinase is essential for human B cell tolerance. J Exp Med. 2004;200(7):927\u201334. https:\/\/doi.org\/10.1084\/jem.20040920.","journal-title":"J Exp Med"},{"issue":"7","key":"2324_CR32","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1093\/emboj\/17.7.1973","volume":"17","author":"AC Fluckiger","year":"1998","unstructured":"Fluckiger AC, Li Z, Kato RM, Wahl MI, Ochs HD, Longnecker R, et al. Btk\/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J. 1998;17(7):1973\u201385. https:\/\/doi.org\/10.1093\/emboj\/17.7.1973.","journal-title":"EMBO J"},{"issue":"10","key":"2324_CR33","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1084\/jem.20011866","volume":"198","author":"M Spaargaren","year":"2003","unstructured":"Spaargaren M, Beuling EA, Rurup ML, Meijer HP, Klok MD, Middendorp S, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med. 2003;198(10):1539\u201350. https:\/\/doi.org\/10.1084\/jem.20011866.","journal-title":"J Exp Med"},{"issue":"12","key":"2324_CR34","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/nri955","volume":"2","author":"H Niiro","year":"2002","unstructured":"Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2(12):945\u201356. https:\/\/doi.org\/10.1038\/nri955.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2324_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","volume":"26","author":"DJJ de Gorter","year":"2007","unstructured":"de Gorter DJJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, et al. Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26(1):93\u2013104. https:\/\/doi.org\/10.1016\/j.immuni.2006.11.012.","journal-title":"Immunity"},{"issue":"8","key":"2324_CR36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.drudis.2014.03.028","volume":"19","author":"JA Whang","year":"2014","unstructured":"Whang JA, Chang BY. Bruton\u2019s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discov Today. 2014;19(8):1200\u20134. https:\/\/doi.org\/10.1016\/j.drudis.2014.03.028.","journal-title":"Drug Discov Today"},{"issue":"4","key":"2324_CR37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","volume":"140","author":"S Torke","year":"2020","unstructured":"Torke S, Pretzsch R, H\u00e4usler D, Haselmayer P, Grenningloh R, Boschert U, et al. Inhibition of Bruton\u2019s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol. 2020;140(4):535\u201348. https:\/\/doi.org\/10.1007\/s00401-020-02204-z.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2324_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","volume":"38","author":"J Rip","year":"2018","unstructured":"Rip J, Van Der Ploeg EK, Hendriks RW, Corneth OBJ. The role of Bruton\u2019s tyrosine kinase in immune cell signaling and systemic autoimmunity. Crit Rev Immunol. 2018;38(1):17\u201362. https:\/\/doi.org\/10.1615\/CritRevImmunol.2018025184.","journal-title":"Crit Rev Immunol"},{"issue":"5","key":"2324_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19(5):289\u2013304. https:\/\/doi.org\/10.1038\/s41582-023-00800-7.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2324_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nchembio.481","volume":"7","author":"JA Di Paolo","year":"2011","unstructured":"Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7(1):41\u201350. https:\/\/doi.org\/10.1038\/nchembio.481.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"2324_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MCHD-0045-2016","volume":"4","author":"S Bournazos","year":"2016","unstructured":"Bournazos S, Wang TT, Ravetch JV. The role and function of Fc\u03b3 receptors on myeloid cells. Microbiol Spectr. 2016;4(6):4.6.20. https:\/\/doi.org\/10.1128\/microbiolspec.MCHD-0045-2016.","journal-title":"Microbiol Spectr"},{"issue":"28","key":"2324_CR42","doi-asserted-by":"publisher","first-page":"26258","DOI":"10.1074\/jbc.M301484200","volume":"278","author":"CA Jefferies","year":"2003","unstructured":"Jefferies CA, Doyle S, Brunner C, Dunne A, Brint E, Wietek C, et al. Bruton\u2019s tyrosine kinase is a Toll\/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem. 2003;278(28):26258\u201364. https:\/\/doi.org\/10.1074\/jbc.M301484200.","journal-title":"J Biol Chem"},{"issue":"4","key":"2324_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14(4):219\u201332. https:\/\/doi.org\/10.1038\/nrc3702.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2324_CR44","first-page":"1224","volume":"8","author":"FM Uckun","year":"2002","unstructured":"Uckun FM, Zheng Y, Cetkovic-Cvrlje M, Vassilev A, Lisowski E, Waurzyniak B, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton\u2019s tyrosine kinase. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(5):1224\u201333.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"1","key":"2324_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li S, Schultz BE, Sprengeler PA, Burrill LC, et al. Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem. 2007;2(1):58\u201361. https:\/\/doi.org\/10.1002\/cmdc.200600221.","journal-title":"ChemMedChem"},{"issue":"2","key":"2324_CR46","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312\u201332. https:\/\/doi.org\/10.1038\/s41375-020-01072-6.","journal-title":"Leukemia"},{"issue":"1","key":"2324_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu A, Lei H, Han X, Wei Y, Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15(1):138. https:\/\/doi.org\/10.1186\/s13045-022-01353-w.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2324_CR48","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10637-025-01513-y","volume":"43","author":"S Gupta","year":"2025","unstructured":"Gupta S, Sharma A, Shukla A, Mishra A, Singh A. From development to clinical success: the journey of established and next-generation BTK inhibitors. Invest New Drugs. 2025;43(2):377\u201393. https:\/\/doi.org\/10.1007\/s10637-025-01513-y.","journal-title":"Invest New Drugs"},{"issue":"10","key":"2324_CR49","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","volume":"202","author":"P Haselmayer","year":"2019","unstructured":"Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, et al. Efficacy and pharmacodynamic modeling of the BTK inhibitor Evobrutinib in autoimmune disease models. J Immunol. 2019;202(10):2888\u2013906. https:\/\/doi.org\/10.4049\/jimmunol.1800583.","journal-title":"J Immunol"},{"issue":"8","key":"2324_CR50","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1111\/all.15261","volume":"77","author":"P Mendes\u2010Bastos","year":"2022","unstructured":"Mendes\u2010Bastos P, Brasileiro A, Kolkhir P, Frischbutter S, Scheffel J, Mo\u00f1ino\u2010Romero S, et al. Bruton\u2019s tyrosine kinase inhibition\u2014an emerging therapeutic strategy in immune\u2010mediated dermatological conditions. Allergy. 2022;77(8):2355\u201366. https:\/\/doi.org\/10.1111\/all.15261.","journal-title":"Allergy"},{"issue":"7","key":"2324_CR51","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","volume":"206","author":"CL Langrish","year":"2021","unstructured":"Langrish CL, Bradshaw JM, Francesco MR, Owens TD, Xing Y, Shu J, et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor Rilzabrutinib for immune-mediated disease. J Immunol. 2021;206(7):1454\u201368. https:\/\/doi.org\/10.4049\/jimmunol.2001130.","journal-title":"J Immunol"},{"issue":"17","key":"2324_CR52","doi-asserted-by":"publisher","first-page":"7643","DOI":"10.1021\/acs.jmedchem.9b00794","volume":"62","author":"RD Caldwell","year":"2019","unstructured":"Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, et al. Discovery of Evobrutinib: an oral, potent, and highly selective, covalent Bruton\u2019s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases. J Med Chem. 2019;62(17):7643\u201355. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00794.","journal-title":"J Med Chem"},{"issue":"28","key":"2324_CR53","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.2174\/0115680266264515230921052521","volume":"23","author":"P Lin","year":"2023","unstructured":"Lin P, Zhang D, Lin J. Clinical research progress of BTK inhibitors in the treatment ofAutoimmune diseases. Curr Top Med Chem. 2023;23(28):2609\u201320. https:\/\/doi.org\/10.2174\/0115680266264515230921052521.","journal-title":"Curr Top Med Chem"},{"key":"2324_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223","author":"GE Ringheim","year":"2021","unstructured":"Ringheim GE, Wampole M, Oberoi K. Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.662223.","journal-title":"Front Immunol"},{"issue":"Supplement_3","key":"2324_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf116.0286","volume":"40","author":"Z Cui","year":"2025","unstructured":"Cui Z, Wang L, Wang C, Xiong Z, Xu G, Yao L, et al. #130 novel Bruton\u2019s tyrosine kinase inhibitor EVER001 in Chinese patients with primary membranous nephropathy: preliminary results from a phase 1b\/2a study. Nephrol Dial Transplant. 2025;40(Supplement_3):gfaf116.0286. https:\/\/doi.org\/10.1093\/ndt\/gfaf116.0286.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2324_CR56","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1541-7786.mcr-20-0814","volume":"19","author":"M Rada","year":"2021","unstructured":"Rada M, Qusairy Z, Massip-Salcedo M, Macip S. Relevance of the Bruton tyrosine kinase as a target for COVID-19 therapy. Mol Cancer Res. 2021;19(4):549\u201354. https:\/\/doi.org\/10.1158\/1541-7786.mcr-20-0814.","journal-title":"Mol Cancer Res"},{"key":"2324_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd0110","author":"M Roschewski","year":"2020","unstructured":"Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/sciimmunol.abd0110.","journal-title":"Sci Immunol"},{"key":"2324_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108816","volume":"230","author":"M Stack","year":"2021","unstructured":"Stack M, Sacco K, Castagnoli R, Livinski AA, Notarangelo LD, Lionakis MS. BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systematic review. Clin Immunol Orlando Fla. 2021;230:108816. https:\/\/doi.org\/10.1016\/j.clim.2021.108816.","journal-title":"Clin Immunol Orlando Fla"},{"key":"2324_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369619","author":"SP Treon","year":"2025","unstructured":"Treon SP, Kotton CN, Park DJ, Moranzoni G, Lemvigh CK, Gathe JC, et al. A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2024.1369619.","journal-title":"Front Immunol"},{"key":"2324_CR60","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160909","author":"L Rijvers","year":"2022","unstructured":"Rijvers L, Van Langelaar J, Bogers L, Melief MJ, Koetzier SC, Blok KM, et al. Human T-bet+ b cell development is associated with BTK activity and suppressed by evobrutinib. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.160909.","journal-title":"JCI Insight"},{"issue":"1","key":"2324_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54430-8","volume":"15","author":"RC Gruber","year":"2024","unstructured":"Gruber RC, Wirak GS, Blazier AS, Lee L, Dufault MR, Hagan N, et al. BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis. Nat Commun. 2024;15(1):10116. https:\/\/doi.org\/10.1038\/s41467-024-54430-8.","journal-title":"Nat Commun"},{"issue":"5","key":"2324_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13240","volume":"34","author":"A Steinmaurer","year":"2024","unstructured":"Steinmaurer A, Riedl C, K\u00f6nig T, Testa G, K\u00f6ck U, Bauer J, et al. The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis. Brain Pathol. 2024;34(5):e13240. https:\/\/doi.org\/10.1111\/bpa.13240.","journal-title":"Brain Pathol"},{"issue":"14","key":"2324_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147641","volume":"22","author":"C Brullo","year":"2021","unstructured":"Brullo C, Villa C, Tasso B, Russo E, Spallarossa A. Btk inhibitors: a medicinal chemistry and drug delivery perspective. Int J Mol Sci. 2021;22(14):7641. https:\/\/doi.org\/10.3390\/ijms22147641.","journal-title":"Int J Mol Sci"},{"key":"2324_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694853","volume":"12","author":"R Zain","year":"2021","unstructured":"Zain R, Vihinen M. Structure-function relationships of covalent and non-covalent BTK inhibitors. Front Immunol. 2021;12:694853. https:\/\/doi.org\/10.3389\/fimmu.2021.694853.","journal-title":"Front Immunol"},{"issue":"2","key":"2324_CR65","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/cts.13162","volume":"15","author":"TD Owens","year":"2022","unstructured":"Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE, et al. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci. 2022;15(2):442\u201350. https:\/\/doi.org\/10.1111\/cts.13162.","journal-title":"Clin Transl Sci"},{"issue":"43","key":"2324_CR66","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.1002\/anie.201601091","volume":"55","author":"TA Baillie","year":"2016","unstructured":"Baillie TA. Targeted covalent inhibitors for drug design. Angew Chem Int Ed Engl. 2016;55(43):13408\u201321. https:\/\/doi.org\/10.1002\/anie.201601091.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"17","key":"2324_CR67","doi-asserted-by":"publisher","first-page":"14693","DOI":"10.1021\/acs.jmedchem.4c01721","volume":"67","author":"DE Heppner","year":"2024","unstructured":"Heppner DE, Ogboo BC, Urul DA, May EW, Schaefer EM, Murkin AS, et al. Demystifying functional parameters for irreversible enzyme inhibitors. J Med Chem. 2024;67(17):14693\u20136. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01721.","journal-title":"J Med Chem"},{"key":"2324_CR68","unstructured":"Johnson A, Harp C, Yu J, et al. Fenebrutinib, a noncovalent, highly selective, long residence time investigational Btk inhibitor for the treatment of MS. ACTRIMS-ECTRIMS Meeting. 11-13 September, 2020. Virtual. In."},{"issue":"12","key":"2324_CR69","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1111\/cts.13407","volume":"15","author":"O Papasouliotis","year":"2022","unstructured":"Papasouliotis O, Mitchell D, Girard P, Dangond F, Dyroff M. Determination of a clinically effective evobrutinib dose: exposure\u2013response analyses of a phase II relapsing multiple sclerosis study. Clin Transl Sci. 2022;15(12):2888\u201398. https:\/\/doi.org\/10.1111\/cts.13407.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"2324_CR70","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","volume":"81","author":"L Goldwirt","year":"2018","unstructured":"Goldwirt L, Beccaria K, Ple A, Sauvageon H, Mourah S. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol. 2018;81(4):783\u20139. https:\/\/doi.org\/10.1007\/s00280-018-3546-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2324_CR71","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1021\/acs.molpharmaceut.8b00702","volume":"15","author":"S Van Hoppe","year":"2018","unstructured":"Van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, et al. P-Glycoprotein (MDR1\/ABCB1) restricts brain penetration of the Bruton\u2019s tyrosine kinase inhibitor Ibrutinib, while Cytochrome P450-3A (CYP3A) limits its oral bioavailability. Mol Pharm. 2018;15(11):5124\u201334. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00702.","journal-title":"Mol Pharm"},{"issue":"1","key":"2324_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/2045-8118-8-7","volume":"8","author":"WM Pardridge","year":"2011","unstructured":"Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS. 2011;8(1):7. https:\/\/doi.org\/10.1186\/2045-8118-8-7.","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"2324_CR73","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/17460441.2015.974545","volume":"10","author":"DB Stanimirovic","year":"2015","unstructured":"Stanimirovic DB, Bani-Yaghoub M, Perkins M, Haqqani AS. Blood\u2013brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics. Expert Opin Drug Discov. 2015;10(2):141\u201355. https:\/\/doi.org\/10.1517\/17460441.2015.974545.","journal-title":"Expert Opin Drug Discov"},{"key":"2324_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177747","volume":"1002","author":"R Pulz","year":"2025","unstructured":"Pulz R, Angst D, Cenni B. Next generation Bruton\u2019s tyrosine kinase inhibitors \u2013 characterization of in vitro potency and selectivity. Eur J Pharmacol. 2025;1002:177747. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177747.","journal-title":"Eur J Pharmacol"},{"key":"2324_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942. https:\/\/doi.org\/10.3389\/fcell.2021.630942.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"2324_CR76","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/nejmoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med. 2022;386(8):735\u201343. https:\/\/doi.org\/10.1056\/nejmoa2114110.","journal-title":"N Engl J Med"},{"issue":"25","key":"2324_CR77","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med. 2019;380(25):2406\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1901981.","journal-title":"N Engl J Med"},{"issue":"4\u20135","key":"2324_CR78","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/13524585241234783","volume":"30","author":"X Montalban","year":"2024","unstructured":"Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, et al. Efficacy and safety results after >35 years of treatment with the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. Mult Scler Houndmills Basingstoke Engl. 2024;30(4\u20135):558\u201370. https:\/\/doi.org\/10.1177\/13524585241234783.","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"11","key":"2324_CR79","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","volume":"23","author":"X Montalban","year":"2024","unstructured":"Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024;23(11):1119\u201332. https:\/\/doi.org\/10.1016\/S1474-4422(24)00328-4.","journal-title":"Lancet Neurol"},{"issue":"12","key":"2324_CR80","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1111\/cts.13407","volume":"15","author":"O Papasouliotis","year":"2022","unstructured":"Papasouliotis O, Mitchell D, Girard P, Dangond F, Dyroff M. Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study. Clin Transl Sci. 2022;15(12):2888\u201398. https:\/\/doi.org\/10.1111\/cts.13407.","journal-title":"Clin Transl Sci"},{"issue":"9","key":"2324_CR81","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4.","journal-title":"Lancet Neurol"},{"issue":"3","key":"2324_CR82","doi-asserted-by":"publisher","DOI":"10.1212\/WN9.0000000000000028","volume":"1","author":"J Oh","year":"2025","unstructured":"Oh J, Fox RJ, Arnold DL, Syed S, Dukovic D, Vargas WS, et al. Tolebrutinib Phase 2b Long-Term Extension Study: Two-Year Safety, MRI, and Clinical Efficacy Outcomes in Patients With Relapsing Multiple Sclerosis. Neurol Open Access. 2025;1(3):e000028. https:\/\/doi.org\/10.1212\/WN9.0000000000000028.","journal-title":"Neurol Open Access."},{"key":"2324_CR83","unstructured":"Reich D, Traboulsee A, Oh J, et al. MRI outcomes from the long-term extension study of tolebrutinib in participants with relapsing multiple sclerosis: 3-year results. ECTRIMS-ACTRIMS Meeting. 11-13 October, 2023. Milan, Italy. In."},{"key":"2324_CR84","unstructured":"Gaitan MI, Raza S, Donnay C, et al. Primary outcome of a phase 2 clinical trial of tolebrutinib, a brain-penetrant BTK inhibitor, for the modulation of chronically inflamed white matter lesions in MS. ACTRIMS Forum. February 29-March 2, 2024. West Palm Beach, FL. In."},{"issue":"1","key":"2324_CR85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-016-1636-z","volume":"133","author":"A Dal-Bianco","year":"2017","unstructured":"Dal-Bianco A, Grabner G, Kronnerwetter C, Weber M, H\u00f6ftberger R, Berger T, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol (Berl). 2017;133(1):25\u201342. https:\/\/doi.org\/10.1007\/s00401-016-1636-z.","journal-title":"Acta Neuropathol (Berl)."},{"issue":"19","key":"2324_CR86","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","volume":"392","author":"J Oh","year":"2025","unstructured":"Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, et al. Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2025;392(19):1893\u2013904. https:\/\/doi.org\/10.1056\/NEJMoa2415985.","journal-title":"N Engl J Med"},{"key":"2324_CR87","unstructured":"Oh J, Arnold DL, Cree BAC, et al. Effects of tolebrutinib on progression independent of relapse activity in the phase 3 GEMINI relapsing MS trials. ECTRIMS. September 24-26, 2025. Barcelona, Spain. In."},{"issue":"19","key":"2324_CR88","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","volume":"392","author":"RJ Fox","year":"2025","unstructured":"Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, et al. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. N Engl J Med. 2025;392(19):1883\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2415988.","journal-title":"N Engl J Med"},{"key":"2324_CR89","unstructured":"Fox J. Tolebrutinib Phase 3 HERCULES Trial in nrSPMS. ECTRIMS. September 18-20, 2025. Barcelona, Spain. In."},{"issue":"1","key":"2324_CR90","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40265-025-02264-z","volume":"86","author":"HA Blair","year":"2026","unstructured":"Blair HA. Tolebrutinib: first approval. Drugs. 2026;86(1):127\u201333. https:\/\/doi.org\/10.1007\/s40265-025-02264-z.","journal-title":"Drugs"},{"key":"2324_CR91","unstructured":"Press Release: U.S. Food and Drug Administration. Complete Response Letter for Tolebrutinib (NDA 219624) for treatment of non-relapsing secondary progressive multiple sclerosis (Dec. 23, 2025). Issued to Sanofi."},{"key":"2324_CR92","unstructured":"Reich D, Bar Or A, Vermersch P et al. Efficacy and safety of tolebrutinib versus placebo in primary progressive multiple sclerosis: results from the phase 3 PERSEUS trial. In ACTRIMS Forum. February 5\u20137, 2026. San Diego, CA."},{"key":"2324_CR93","unstructured":"Giovannoni G, Airas L, Bove R, et al. Ocrelizumab vs Placebo in Primary Progressive MS: Efficacy and Safety Results of the Phase IIIb ORATORIO-HAND Study. ECTRIMS. September 24-26, 2025. Barcelona, Spain. In."},{"issue":"3","key":"2324_CR94","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1606468.","journal-title":"N Engl J Med"},{"key":"2324_CR95","unstructured":"Press Release: Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis.\u201d Sanofi, 15 Dec. 2025."},{"issue":"10","key":"2324_CR96","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.3390\/ijms25105246","volume":"25","author":"K Wi\u015bniewski","year":"2024","unstructured":"Wi\u015bniewski K, Pu\u0142a B. A Review of Resistance Mechanisms to Bruton\u2019s Kinase Inhibitors in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2024;25(10):5246. https:\/\/doi.org\/10.3390\/ijms25105246.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2324_CR97","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","volume":"24","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or A, Dufek M, Budincevic H, Drulovic J, Habek M, Hua LH, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24(8):656\u201366. https:\/\/doi.org\/10.1016\/S1474-4422(25)00174-7.","journal-title":"Lancet Neurol"},{"key":"2324_CR98","unstructured":"Bar-Or A, Oh J, Dufek M, et al. Fenebrutinib maintains low disease activity in relapsing multiple sclerosis: Results from the FENopta Open-Label Extension. CMSC. May 28-31. Phoenix, AZ. In."},{"key":"2324_CR99","unstructured":"Press release: Roche\u2019s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis. November 9, 2025."},{"key":"2324_CR100","unstructured":"Press Release: Roche\u2019s fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1). March 1, 2026."},{"key":"2324_CR101","unstructured":"Bar-Or A, Oh J, Giovannoni G, et al. Efficacy and safety of fenebrutinib vs ocrelizumab in primary progressive multiple sclerosis: primary results of the phase III FENtrepid study. ACTRIMS Forum. February 7. San Diego, CA. In."},{"key":"2324_CR102","unstructured":"Wollinsky JS, Montalban X, Hauser SL, et al. Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the phase III ORATORIO study. Consortium of Multiple Sclerosis Centers (CMSC); May 30-June 2; Nashville, TN. In."},{"key":"2324_CR103","unstructured":"Xu Y, et al. Orelabrutinib in Relapsing-Remitting Multiple Sclerosis: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. ACTRIMS Forum 2025. February 27-March 1, 2025. West Palm Beach, FL. In."},{"issue":"6","key":"2324_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1295","volume":"10","author":"E Bame","year":"2021","unstructured":"Bame E, Tang H, Burns JC, Arefayene M, Michelsen K, Ma B, et al. Next-generation Bruton\u2019s tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells. Clin Transl Immunol. 2021;10(6):e1295. https:\/\/doi.org\/10.1002\/cti2.1295.","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"2324_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00315-9","volume":"11","author":"H Wang","year":"2022","unstructured":"Wang H, Guo H, Yang J, Liu Y, Liu X, Zhang Q, et al. Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect. Exp Hematol Oncol. 2022;11(1):60. https:\/\/doi.org\/10.1186\/s40164-022-00315-9.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2324_CR106","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology. 2020;2020(1):336\u201345. https:\/\/doi.org\/10.1182\/hematology.2020000118.","journal-title":"Hematology"},{"issue":"1","key":"2324_CR107","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/cid\/cix687","volume":"66","author":"G Chamilos","year":"2018","unstructured":"Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis. 2018;66(1):140\u20138. https:\/\/doi.org\/10.1093\/cid\/cix687.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2324_CR108","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cmi.2024.12.032","volume":"31","author":"C Gibert","year":"2025","unstructured":"Gibert C, Blaize M, Fekkar A. Fungal infection in patients treated with Bruton tyrosine kinase inhibitor\u2014from epidemiology to clinical outcome: a systematic review. Clin Microbiol Infect. 2025;31(5):731\u20139. https:\/\/doi.org\/10.1016\/j.cmi.2024.12.032.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2324_CR109","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ejh.13020","volume":"100","author":"BF Tillman","year":"2018","unstructured":"Tillman BF, Pauff JM, Satyanarayana G, Talbott M, Warner JL. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2018;100(4):325\u201334. https:\/\/doi.org\/10.1111\/ejh.13020.","journal-title":"Eur J Haematol"},{"issue":"11","key":"2324_CR110","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"issue":"13","key":"2324_CR111","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.056.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2324_CR112","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1509388.","journal-title":"N Engl J Med"},{"issue":"26","key":"2324_CR113","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, et al. Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-Cell Lymphoma. N Engl J Med. 2022;386(26):2482\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2201817.","journal-title":"N Engl J Med"},{"issue":"10","key":"2324_CR114","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1177\/13524585221091060","volume":"28","author":"DL Rotstein","year":"2022","unstructured":"Rotstein DL. All Bruton\u2019s tyrosine kinase inhibitors have similar efficacy and risks: no. Mult Scler (Houndmills Basingstoke Engl). 2022;28(10):1500\u20132. https:\/\/doi.org\/10.1177\/13524585221091060.","journal-title":"Mult Scler (Houndmills Basingstoke Engl)"},{"issue":"1","key":"2324_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","volume":"94","author":"X Montalban","year":"2023","unstructured":"Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, et al. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in Multiple Sclerosis, Rheumatoid Arthritis and Systemic Lupus Erythematosus: an integrated safety analysis. J Neurol Neurosurg Psychiatry. 2023;94(1):1\u20139. https:\/\/doi.org\/10.1136\/jnnp-2022-328799.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2324_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010852","volume":"24","author":"L Meunier","year":"2023","unstructured":"Meunier L, Larrey D. Hepatotoxicity of drugs used in Multiple Sclerosis, diagnostic challenge, and the role of HLA genotype susceptibility. Int J Mol Sci. 2023;24(1):852. https:\/\/doi.org\/10.3390\/ijms24010852.","journal-title":"Int J Mol Sci"},{"key":"2324_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1413985","volume":"15","author":"L Ke","year":"2024","unstructured":"Ke L, Li S, Huang D, Wang Y. Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in Chronic Lymphocytic Leukemia: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1413985. https:\/\/doi.org\/10.3389\/fphar.2024.1413985.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2324_CR118","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40744-019-00182-7","volume":"7","author":"PH Schafer","year":"2020","unstructured":"Schafer PH, Kivitz AJ, Ma J, Korish S, Sutherland D, Li L, et al. Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with Rheumatoid Arthritis: results from a mechanistic study. Rheumatol Ther. 2020;7(1):101\u201319. https:\/\/doi.org\/10.1007\/s40744-019-00182-7.","journal-title":"Rheumatol Ther"},{"key":"2324_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704","volume":"11","author":"SM O\u2019Brien","year":"2021","unstructured":"O\u2019Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11:720704. https:\/\/doi.org\/10.3389\/fonc.2021.720704.","journal-title":"Front Oncol"},{"issue":"5","key":"2324_CR120","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/ejh.13148","volume":"101","author":"J Chen","year":"2018","unstructured":"Chen J, Kinoshita T, Gururaja T, Sukbuntherng J, James D, Lu D, et al. The effect of Bruton\u2019s tyrosine kinase ( BTK ) inhibitors on collagen\u2010induced platelet aggregation, BTK , and tyrosine kinase expressed in Hepatocellular Carcinoma ( TEC ). Eur J Haematol. 2018;101(5):604\u201312. https:\/\/doi.org\/10.1111\/ejh.13148.","journal-title":"Eur J Haematol"},{"issue":"3","key":"2324_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18030371","volume":"18","author":"E Robak","year":"2026","unstructured":"Robak E, Robak T. Cutaneous adverse effects in patients treated with BTK inhibitors. Cancers (Basel). 2026;18(3):371. https:\/\/doi.org\/10.3390\/cancers18030371.","journal-title":"Cancers (Basel)"},{"issue":"26","key":"2324_CR122","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1812836.","journal-title":"N Engl J Med"},{"issue":"7","key":"2324_CR123","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/nejmoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-Cell depletion with Rituximab in relapsing\u2013remitting Multiple Sclerosis. N Engl J Med. 2008;358(7):676\u201388. https:\/\/doi.org\/10.1056\/nejmoa0706383.","journal-title":"N Engl J Med"},{"issue":"1","key":"2324_CR124","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200056","volume":"10","author":"C Starvaggi Cucuzza","year":"2023","unstructured":"Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, et al. Sustained low relapse rate with highly variable B-Cell repopulation dynamics with extended Rituximab dosing intervals in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200056. https:\/\/doi.org\/10.1212\/NXI.0000000000200056.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"2324_CR125","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200152","volume":"10","author":"R Claverie","year":"2023","unstructured":"Claverie R, Perriguey M, Rico A, Boutiere C, Demortiere S, Durozard P, et al. Efficacy of Rituximab outlasts B-Cell repopulation in Multiple Sclerosis: Time to rethink dosing? Neurol Neuroimmunol Neuroinflamm. 2023;10(5):e200152. https:\/\/doi.org\/10.1212\/NXI.0000000000200152.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"18","key":"2324_CR126","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1080\/14656566.2022.2144218","volume":"23","author":"D Gu","year":"2022","unstructured":"Gu D, Li J, Miao Y. Evaluating Orelabrutinib as a novel treatment option for relapsed\/refractory chronic lymphocytic leukemia in China. Expert Opin Pharmacother. 2022;23(18):1979\u201386. https:\/\/doi.org\/10.1080\/14656566.2022.2144218.","journal-title":"Expert Opin Pharmacother"},{"key":"2324_CR127","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation [Internet]. 2009 Jul [cited 2025 Nov 8]. Report No. Available from: https:\/\/www.fda.gov\/media\/116737\/download"},{"issue":"2","key":"2324_CR128","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/17425255.2015.983075","volume":"11","author":"YL Teo","year":"2015","unstructured":"Teo YL, Ho HK, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: A literature review. Expert Opin Drug Metab Toxicol. 2015;11(2):231\u201342. https:\/\/doi.org\/10.1517\/17425255.2015.983075.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2324_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118462","volume":"191","author":"ME Shaker","year":"2025","unstructured":"Shaker ME, Shaaban AA, Gomaa HAM, Abdelgawad MA, El-Mesery M, Hazem SH. The novel Bruton tyrosine kinase inhibitor Branebrutinib abrogates lipopolysaccharide\/galactosamine-induced hepatic injury via limiting inflammation and oxidative stress. Biomed Pharmacother. 2025;191:118462. https:\/\/doi.org\/10.1016\/j.biopha.2025.118462.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"2324_CR130","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208058","volume":"102","author":"DL Arnold","year":"2024","unstructured":"Arnold DL, Elliot C, Martin EC, et al. Effect of Evobrutinib on slowly expanding lesion volume in relapsing Multiple Sclerosis: A post hoc analysis of a phase 2 trial. Neurology. 2024;102(5):e208058. https:\/\/doi.org\/10.1212\/WNL.0000000000208058.","journal-title":"Neurology"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02324-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02324-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02324-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:40:01Z","timestamp":1782196801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02324-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":130,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2324"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02324-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jeffrey Lambe has no relevant disclosures. Robert J Fox received personal consulting fees from Astoria Biologica, Biogen, Bristol Myers Squibb, Cognito, Galvani, Immunic, INmune Bio, InnoCare Pharma, Kiniksa, Novartis, Sanofi, SetPoint Medical, Siemens, Sudo Bioscience, and TG Therapeutics; served on advisory committees for AB Science, Biogen, Immunic, Novartis, and Sanofi; and received clinical trial contract and research grant funding from Sanofi and Synaptogenix.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Both authors contributed equally to this work. Both authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}